Pharmalot -- Just one month after agreeing to buy Penwest Pharmaceuticals for $144 million, Endo Pharmaceuticals is in the process of laying off sales managers and sales reps, according to sources. The exact number of jobs to be eliminated is unclear at the moment, but we are told Endo is engaging InVentiv, a contract sales organization, to provide replacements and lower expenses. We await a reply from Endo.
